CAR-T Cell Therapy for Solid Tumors: Are we Still That Far? a Systematic Review of Literature.
Cancer Invest
; 40(10): 923-937, 2022 Nov.
Article
em En
| MEDLINE
| ID: mdl-36102932
ABSTRACT
This systematic review aims to assess all the prospective studies published to date on the efficacy of CAR-T cell therapy in solid tumors. Databases searched were PubMed and Google Scholar from inception through May 1st 2021. Search query was (Chimeric antigen receptor) or (CAR-T) or (T-CAR). Twenty-nine prospective studies (265 patients) were included. Most published clinical trials are phase I. Clinical benefit was 100% in epithelial ovarian cancer, 70-82% in gastrointestinal tumors, 79% in mesothelioma, 63% in small-cell lung cancer, 24-67% in sarcoma, 50-62% in prostate cancer, and 45-50% in central nervous system tumors. No serious CAR-T cell specific serious toxicities were noted.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Receptores de Antígenos Quiméricos
/
Neoplasias Gastrointestinais
Tipo de estudo:
Observational_studies
/
Systematic_reviews
Limite:
Humans
/
Male
Idioma:
En
Revista:
Cancer Invest
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Líbano